Biologically, the expression of PD-L1 on the cancer tissues contributes to the regulation of tumorigenesis, and from a clinical standpoint, the percentage of expression of PD-L1 is measured on tumor biopsy, as shown in Figure 1, to predict the patient response to anti-PD1 treatment. This evidence concerns the gene CD274 and neoplasm.